At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 51 enrolled
Drug / intervention
QMF149drug
Likely dose
QMF149 320 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QMF149 in Japanese Patients With Asthma
In Brief
A Phase 3 clinical trial evaluating QMF149 for Asthma. Completed, enrolled 51 participants across 15 sites.
Detailed Summary
The purpose of this study was to provide long term safety data of QMF149 in Japanese participants with inadequately controlled asthma for the registration of QMF149 in Japan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartApr 2017
Primary CompletionJul 2018
Study CompletionFeb 2019
TodayJul 2026
First PostedApr 4, 2017
Enrollment StartApr 25, 2017
Primary CompletionJul 19, 2018
Study CompletionFeb 12, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.2 years ago
Interventions
QMF149drug
QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler